Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Appears in Networks 8

In-Edges 27

act(a(CHEBI:amphetamine)) increases bp(GO:locomotion) View Subject | View Object

Both VU0152100 and VU0152099 effectively reversed amphetamine-induced hyperlocomotion, demonstrating antipsychotic-like activity in preclinical models. PubMed:24511233

p(MGI:App, var("p.Lys670Asn"), var("p.Met671Leu"), var("p.Thr714Ile"), var("p.Val717Ile")) increases bp(GO:locomotion) View Subject | View Object

The locomotor behavior during the NOR habituation phase was measured by the total distance traveled: APP-WT showed higher locomotor activity compared with GFP-WT (p = 0.0027; Fig. 2F) PubMed:27522251

p(MGI:Tmem35a) decreases bp(GO:locomotion) View Subject | View Object

General characterization showed that the knockout mice as compared to their wild-type littermates show no changes in body weight, have slight increases in body temperature (Figures S3A and S3B), and exhibit significantly enhanced locomotor activity (Figures S2A and S2B) PubMed:28445721

p(MGI:Tmem35a) decreases bp(GO:locomotion) View Subject | View Object

The NACHO knockouts showed increased total number of arm entries in the Y-maze, which fits with their enhanced locomotor activity (Figure S2F) PubMed:28445721

a(HBP:"4-OH-GTS-21") causesNoChange bp(GO:locomotion) View Subject | View Object

4OH-GTS-21 had no effect on the latency to enter the dark chamber during avoidance training (Fig. 1 ) or on swim speed in the Morris water task (data not shown), indicating that it had no discernible effect on locomotor function PubMed:17640819

a(CHEBI:"amyloid-beta") increases bp(GO:locomotion) View Subject | View Object

Transgenic mouse models of AD overexpressing Aβ peptides generally show greater locomotor activity and disinhibition in the elevated plus maze compared to non-transgenic mice, suggest- ing hyperactivity and a lower level of anxiety [28–30]. PubMed:26010758

a(CHEBI:Anatabine) decreases bp(GO:locomotion) View Subject | View Object

Interestingly, the hyper- active behavior of Tg PS1/APPswe mice was suppressed with the anatabine treatment at a dos- age of 20 mg/Kg/Day (Fig 2B and 2C). PubMed:26010758

a(CHEBI:"methylene blue") increases bp(GO:locomotion) View Subject | View Object

We supplemented the growth medium of syn- chronized L1 larvae (pro-aggregant strain) with 25 m M MB and measured their locomotion speed as day 1 young adults. This treatment led to 15% amelioration of locomotion (Sup- plementary Material, Fig. S6A). PubMed:22611162

a(HBP:bb14) increases bp(GO:locomotion) View Subject | View Object

We then applied, in the 96-well liquid culture format, the two most promising hit compounds obtained in a mammalian cell model of Tau toxicity (57), namely the phenylthiazolyl- hydrazide derivatives Bsc3094 and bb14, and observed a similar amelioration effect in locomotion (Supplementary Ma- terial, Fig. S6B). PubMed:22611162

a(HBP:cmp16) increases bp(GO:locomotion) View Subject | View Object

At 100 m M , we observed improved locomotion of treated animals. These animals moved approximately 1.6 times faster than DMSO-treated controls (Fig. 9A). PubMed:22611162

a(PUBCHEM:25096749) increases bp(GO:locomotion) View Subject | View Object

We then applied, in the 96-well liquid culture format, the two most promising hit compounds obtained in a mammalian cell model of Tau toxicity (57), namely the phenylthiazolyl- hydrazide derivatives Bsc3094 and bb14, and observed a similar amelioration effect in locomotion (Supplementary Ma- terial, Fig. S6B). PubMed:22611162

p(HGNC:MAPT, var("p.Lys280del")) decreases bp(GO:locomotion) View Subject | View Object

The motility of the pro-aggregant worms was considerably enhanced upon apply- ing RNAi against F3DK280 (speed ¼ 70.7 + 17 mm/s for RNAi-treated versus 40.3 + 17 for control), whereas the anti- aggregant worms showed no difference upon treatment (Sup- plementary Material, Fig. S1C). PubMed:22611162

a(CHEBI:"methylene blue") positiveCorrelation bp(GO:locomotion) View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

a(CHEBI:azaperone) increases bp(GO:locomotion) View Subject | View Object

The antipsychotic drug azaperone shows neuroprotective effects, improves locomotion, reduces the insoluble tau, and partially abates the neurodegeneration in this tauopathy model (104). PubMed:29191965

a(HBP:"Phenylthiazolyl-hydrazide") positiveCorrelation bp(GO:locomotion) View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

a(PUBCHEM:6475963) positiveCorrelation bp(GO:locomotion) View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

bp(GO:aging) decreases bp(GO:locomotion) View Subject | View Object

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

composite(a(CHEBI:ethosuximide), p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met"))) increases bp(GO:locomotion) View Subject | View Object

In a recent study, the antiepileptic drug ethosuximide increased the lifespan and partially corrected the Unc phenotype in TauV337M worms with the effect dependent on the insulin signaling pathway (106). PubMed:29191965

p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met")) decreases bp(GO:locomotion) View Subject | View Object

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

composite(p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met")), p(HGNC:BAIAP3)) decreases bp(GO:locomotion) View Subject | View Object

Indeed, 2 of the candidates identified in an RNAi screen that worsened the Unc phenotype in the TauV337M worm, called enhancers of tauopathy, were postsynaptic (80). PubMed:29191965

composite(p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met")), p(HGNC:CHRNA7)) decreases bp(GO:locomotion) View Subject | View Object

Indeed, 2 of the candidates identified in an RNAi screen that worsened the Unc phenotype in the TauV337M worm, called enhancers of tauopathy, were postsynaptic (80). PubMed:29191965

composite(p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met")), p(HGNC:DDC)) decreases bp(GO:locomotion) View Subject | View Object

Loss of bas-1 function improved the motor function, reduced insoluble tau and its phosphorylation and ameliorated the tau-induced neurodegeneration without increasing the longevity in TauV337M worms PubMed:29191965

composite(p(HBP:"Tau isoform E (412 aa)", var("p.Val337Met")), p(HGNC:ZC3H14)) decreases bp(GO:locomotion) View Subject | View Object

Eliminating sut-2 resulted in partial recovery of Unc phenotype, less neurodegeneration and reduction of insoluble tau in the TauV337M worm; whereas sut-2 overexpression exacerbated the pathology PubMed:29191965

p(HBP:"Tau isoform E (412 aa)", var("p.Pro301Leu")) decreases bp(GO:locomotion) View Subject | View Object

Three transgenic lines were generated based on 1N4R wild-type MAPT or its FTD-17 mutant variants P301L and V337M. The mutant lines showed a stronger Unc phenotype than the wild-type tau lines and the severity of the Unc phenotype progressed with age PubMed:29191965

p(HBP:"Tau isoform Fetal-tau (352 aa)") decreases bp(GO:locomotion) View Subject | View Object

The transgenic lines exhibited a progressive age-associated Unc phenotype, with or without phospho-mimicking mutations PubMed:29191965

p(HBP:"Tau isoform Fetal-tau (352 aa)", pmod(HBP:hyperphosphorylation)) decreases bp(GO:locomotion) View Subject | View Object

The transgenic lines exhibited a progressive age-associated Unc phenotype, with or without phospho-mimicking mutations PubMed:29191965

p(HGNC:MAPT) increases bp(GO:locomotion) View Subject | View Object

Intraneuronal iron accumulation, neuronal loss in the substantia nigra and a severe decline in locomotor functions were observed in 12‑month-old tau-knockoutmice PubMed:26631930

Out-Edges 3

bp(GO:locomotion) positiveCorrelation a(CHEBI:"methylene blue") View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

bp(GO:locomotion) positiveCorrelation a(PUBCHEM:6475963) View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

bp(GO:locomotion) positiveCorrelation a(HBP:"Phenylthiazolyl-hydrazide") View Subject | View Object

For example, Fatouros et al. (68) tested several tau-aggregation inhibitor compounds such as methylene blue, a rhodanine derivative (bb14), and a phenylthiazolyl hydrazide derivative (BSc3094), which reduce the insoluble tau and partially suppress the Unc phenotype. PubMed:29191965

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.